Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery Mohammad MahmoudianSara SalatinAhmad Yari Khosroushahi Review Article 18 June 2018 Pages: 371 - 382
Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer Xiao-fang GuoSai-sai LiDuan Liu Original Article 16 June 2018 Pages: 383 - 394
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel Chao XuPatanjali RavvaFrançois Mercier Original Article 18 June 2018 Pages: 395 - 406
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer Amita PatnaikMichael GordonDavid Hong Original Article Open access 20 June 2018 Pages: 407 - 418
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer Amita PatnaikMichael GordonDavid Hong Correction 16 July 2018 Pages: 419 - 419
Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients Sreenivasulu PalugullaPanneer DevarajuJayanthi Mathaiyan Original Article 23 June 2018 Pages: 421 - 428
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies James J. HardingRichard K. DoGhassan K. Abou-Alfa Original Article 03 July 2018 Pages: 429 - 440
Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin L. van AndelH. RosingJ. H. Beijnen Original Article 04 July 2018 Pages: 441 - 455
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer Bodine P. S. I. BelderbosRonald de WitFred Saad Original Article Open access 05 July 2018 Pages: 457 - 468
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis Jong Hwan ChoiWoo Jin ChungSung Bum Cho Original Article 07 July 2018 Pages: 469 - 478
Brazilin induces FOXO3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells Yan KangPeiheng HeBowen Wu Original Article 09 July 2018 Pages: 479 - 491
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors Paul J. WoodRobyn StrongDavid M. Ashley Original Article 09 July 2018 Pages: 493 - 503
Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma Guofu ChenLiming ShengXianghui Du Original Article 09 July 2018 Pages: 505 - 510
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors Junji FuruseTakayasu KurataKazuhiko Nakagawa Original Article Open access 10 July 2018 Pages: 511 - 519
Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer Shravanti BhowmikSubhas BhowmickThennati Rajamannar Original Article 11 July 2018 Pages: 521 - 532
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors Laeeq MalikAnthony ZwiebelJames Cooper Original Article 18 July 2018 Pages: 533 - 539
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies Millie DasSukhmani K. PaddaHeather A. Wakelee Original Article 20 July 2018 Pages: 541 - 550
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation Dehua LiaoDunwu YaoChunhua Zhou Original Article 23 July 2018 Pages: 551 - 559
A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib Lixia JuMingquan HanZhengwei Dong Clinical Trial Report 06 August 2018 Pages: 561 - 564
A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat Cody J. PeerOliver M. HallWilliam D. Figg Short Communication 27 June 2018 Pages: 565 - 570
